학술논문
Real‐world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center.
Document Type
Article
Author
Source
Subject
*TERMINATION of treatment
*BIOLOGICALS
*PSORIASIS
*PSORIATIC arthritis
*DRUGS
*THERAPEUTICS
*
*
*
*
*
Language
ISSN
1396-0296
Abstract
Drug survival of biologic agents was defined as the time from initiation to discontinuation.2 The median survival time for all-cause treatment discontinuation was 444 days (95% CI: 361, 525) (Table 1). Real-world drug survival and reasons for treatment discontinuation of biologics and apremilast in patients with psoriasis in an academic center 7 Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. [Extracted from the article]